The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

<p><strong>Introduction</strong> Symptoms reported following the administration of investigational drugs play an important role in decisions for registration and treatment guidelines. However, symptoms are subjective, and interview methods to quantify them are difficult to standard...

Bibliografske podrobnosti
Main Authors:	Thriemer, K, Commons, RJ, Rajasekhar, M, Degaga, TS, Chand, K, Chau, NH, Assefa, A, Naddim, MN, Pasaribu, AP, Rahim, AG, Sutanto, I, Hien, TT, Hailu, A, Hasanzai, MA, Ekawati, LL, Woyessa, A, Teferi, T, Waithira, N, Taylor, WRJ, Ley, B, Dondorp, A, Baird, JK, White, NJ, Day, NP, Price, RN, Simpson, JA, von Seidlein, L
Format:	Journal article
Jezik:	English
Izdano:	BioMed Central 2023

Podobne knjige/članki

Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency
od: Taylor, WRJ, et al.
Izdano: (2023)

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
od: Taylor, WRJ, et al.
Izdano: (2019)

Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned
od: Degaga, TS, et al.
Izdano: (2020)

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
od: Thriemer, K, et al.
Izdano: (2022)

Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial
od: Thriemer, K, et al.
Izdano: (2022)

Primaquine for plasmodium vivax malaria treatment – authors' reply
od: Price, RN, et al.
Izdano: (2020)

Adapting international clinical trials during COVID-19 and beyond
od: Thriemer, K, et al.
Izdano: (2023)

Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
od: Mehdipour, P, et al.
Izdano: (2023)

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis
od: Fadilah, I, et al.
Izdano: (2024)

Plasmodium vivax in the era of the shrinking P. falciparum map
od: Price, RN, et al.
Izdano: (2020)

G6PD Deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: A prospective observational study.
od: Ley, B, et al.
Izdano: (2016)

Economic costs of Plasmodium vivax episodes: a multi-country comparative analysis using primary trial data
od: Devine, A, et al.
Izdano: (2018)

The haematological consequences of plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
od: Commons, RJ, et al.
Izdano: (2019)

The worldwide antimalarial resistance network clinical trials publication library: A live, open-access database of plasmodium treatment efficacy trials
od: Takata, J, et al.
Izdano: (2020)

Provider and household costs of Plasmodium vivax malaria episodes: A multicountry comparative analysis of primary trial data
od: Devine, A, et al.
Izdano: (2019)

The cardiotoxicity of antimalarials
Izdano: (2017)

Tafenoquine for children: a step towards implementation
od: Commons, RJ, et al.
Izdano: (2021)

The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
od: Commons, RJ, et al.
Izdano: (2018)

In vivo assessments to detect antimalarial resistance
od: Dhorda, M, et al.
Izdano: (2019)

World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs.
od: Price, R, et al.
Izdano: (2007)

World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
od: Price, R, et al.
Izdano: (2007)

Antimalarial drug resistance
od: White, N
Izdano: (2004)

Cardiotoxicity of antimalarial drugs.
od: White, N
Izdano: (2007)

Antimalarial drug resistance.
od: White, N
Izdano: (2004)

Effectiveness of antimalarial drugs.
od: Baird, J
Izdano: (2005)

Toxicity of antimalarial drugs.
od: Peto, T
Izdano: (1989)

Counterfeit artesunate antimalarials in southeast Asia.
od: Newton, P, et al.
Izdano: (2003)

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis
od: Chan, XHS, et al.
Izdano: (2021)

Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
od: Barnes, K, et al.
Izdano: (2005)

A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria
od: Sadhewa, A, et al.
Izdano: (2023)

Field evaluation of a novel semi-quantitative point-of-care diagnostic for G6PD deficiency in Indonesia
od: Sadhewa, A, et al.
Izdano: (2024)

Monitoring antimalarial drug efficacy - Reply
od: Mayxay, M, et al.
Izdano: (2004)

Antimalarial drugs in pregnancy: a review.
od: Nosten, F, et al.
Izdano: (2006)

Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
od: Tripura, R, et al.
Izdano: (2022)

Evaluation of CareStart™ malaria HRP2/pLDH (Pf/PAN) combo rapid diagnostic test for diagnosis of Plasmodium falciparum infection in malaria co-endemic areas in association with parasite density
od: Christian, M, et al.
Izdano: (2025)

Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.
od: Dondorp, A, et al.
Izdano: (2004)

Clinical Pharmacology Of Antimalarial Drugs.
Izdano: (1989)

Adverse effects of antimalarials. An update.
od: Luzzi, G, et al.
Izdano: (1993)

SCHIZONTOCIDAL ANTIMALARIALS - A REPLY
od: White, N, et al.
Izdano: (1990)

Antimalarial pharmacokinetics and treatment regimens.
od: White, N
Izdano: (1992)